Table 3.
Demographic and clinical features of polymorphism carriers.
| Type of polymorphism | R702W | G881R | 3020insC | Double variant |
|---|---|---|---|---|
| Number of patients | 25 | 15 | 13 | 10 |
| Age of onset (yrs) | 24.5 (19-31.25) | 29 (20-38) | 22.5 (19.25-26.5) | 28 (16-42.5) |
| Δ diagnosis-surgery (months) | 12 (4-12) | 10 (6-43) | 36 (12-84) | 24 (12-55)∗ |
| Gender | ||||
| Male | 15 (60%) | 10 (67%) | 6 (46%) | 9 (90%) |
| Female | 10 (40%) | 5 (33%) | 7 (54%) | 1 (10%) |
| Smoking habit | ||||
| No | 6 (27%) | 10 (72%) | 7 (58%) | 3 (33%) |
| Yes | 9 (41%) | 2 (14%) | 3 (25%) | 4 (45%) |
| Former | 7 (32%) | 2 (14%) | 2 (17%) | 2 (22%) |
| Disease status | ||||
| Quiescent | 17 (85%) | 8 (61%) | 9 (82%) | 3 (43%) |
| Active | 3 (15%) | 5 (39%) | 2 (18%) | 4 (57%) |
| Disease location | p = 0.0527 | |||
| Ileo | 15 (60%) | 8 (53%) | 11 (84%) | 2 (20%) |
| Colon | 2 (8%) | 0 | 1 (8%) | 2 (20%) |
| Ileocolon | 8 (32%) | 7 (47%) | 1 (8%) | 6 (60%) |
| Disease behavior | ||||
| Inflammatory | 1 (4%) | 1 (7%) | 1 (8%) | 1 (12%) |
| Stricturing | 11 (46%) | 7 (46%) | 3 (25%) | 4 (44%) |
| Fistulising | 2 (8%) | 1 (7%) | 3 (25%) | 2 (22%) |
| Stricturing and fistulising | 10 (42%) | 6 (40%) | 5 (42%) | 2 (22%) |
| Extraintestinal disease | ||||
| Skin | 4 (19%) | 2 (14%) | 1 (9%) | 1 (14%) |
| Arthritis | 7 (33%) | 4 (28%) | 5 (45%) | 2 (28%) |
| Perianal fistulae | 10 (40%) | 4 (27%) | 4 (33%) | 6 (60%) |
| Medication responsiveness | ||||
| Mesalazine | 18 (95%) | 9 (75%) | 11 (100%) | 6 (86%) |
| Steroids | 16 (84%) | 9 (64%) | 11 (100%) | 8 (89%) |
| Azathioprine | 15 (100%) | 5 (55%) | 4 (44%) | 4 (80%)∗ |
| Infliximab | 4 (50%) | 1 (25%) | 5 (100%) | 3 (75%) |
| Adalimumab | 9 (82%) | 4 (67%) | 7 (78%) | 1 (50%) |
| Type of surgery | ||||
| Resection | 18 (86%) | 12 (80%) | 10 (83%) | 9 (90%) |
| Resection+SXPL | 3 (14%) | 3 (20%) | 2 (17%) | 1 (10%) |
| Recurrence | 9 (43%) | 8 (53%) | 8 (67%) | 6 (67%) |
| Multiple operations (≥2) | 9 (41%) | 9 (60%) | 8 (67%) | 8 (80%) |
| History of urgent surgery | 2 (9%) | 5 (33%) | 3 (25%) |
p = 0.673 5 (50%) |
| Minimum surgery-free interval (yrs) | 5.058 ± 2.02 | 7.796 ± 2.8 | 7.886 ± 2.6 | 4.157 ± 2.7 |
| Mean surgery-free interval (yrs) | 5.81 ± 1.9 | 8.133 ± 2.7 | 9.438 ± 2.2 | 5.957 ± 2.5 |
| Digestive and/or extraintestinal cancer | 1 (4%) | 1 (7%) | 2 (14%) | 0 |
| Immunological comorbidity | ||||
| Autoimmunity | 3 (15%) | 1 (8%) | 3 (27%) | 1 (14%) |
| Asthma | 1 (5%) | 0 | 2 (18%) | 1 (14%) |
| Allergies | 9 (45%) | 5 (36%) | 6 (54%) | 1 (12%) |
| Familial IBD | 6 (33%) | 5 (36%) | 1 (10%) | 1 (11%) |
Data are mean ± SE or median (interquartile range 25–75) for continuous variables and number (percentage) for categorical variable. ∗p < 0.05, ∗∗p < 0.01 WT vs. etero+omo, by χ2 or Kruskal-Wallis test.